Bull case
CRISPR Therapeutics is viewed positively because CTX310 is showing a compelling one-time gene-editing profile, with a 0.8 mg/kg dose producing a mean 78.6% reduction in ANGPTL3 one year post-dose and durable effects across key cardiovascular biomarkers without new treatment-related adverse events or delayed liver toxicity. The company’s first approved therapy, Casgevy, provides an important commercial anchor, while the bull case assumes sales can exceed expectations on strong reimbursement and the broader pipeline can progress toward commercialization or strategic acquisition. More broadly, the focus on genetically defined diseases, especially severe hypertriglyceridemia and refractory hypercholesterolemia, gives CRISPR Therapeutics a differentiated therapeutic proposition versus chronic modalities like siRNA, mAbs, or oral lipid-lowering drugs.